NCT03195387 - Chemoprotective Activity of MMV390048 in PfSPZ Challenge Model | Biotech Hunter

Timeline

Start Date

January 31, 2018

Primary Completion Date

September 30, 2018

Study Completion Date

December 31, 2018

Conditions

Malaria,Falciparum

Interventions

DRUG

MMV390048

Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).

Trial Locations (1)

72074

Institute of Tropical Medicine / Centre for Clinical Trials, Eberhard Karls University, Tübingen